Drug Profile
UB 221
Alternative Names: UB-221Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Chinese Academy of Sciences
- Developer Chinese Academy of Sciences; United BioPharma
- Class Antiallergics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action IgE receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chronic urticaria
- No development reported Allergic asthma; Allergic rhinitis; Atopic dermatitis; Food hypersensitivity
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for clinical-Phase-Unknown development in Allergic-asthma in Taiwan (IV, Infusion)
- 28 Dec 2022 No recent reports of development identified for clinical-Phase-Unknown development in Allergic-rhinitis in Taiwan (IV, Infusion)
- 28 Dec 2022 No recent reports of development identified for clinical-Phase-Unknown development in Atopic-dermatitis in Taiwan (IV, Infusion)